Manulife's Fee-Based Pivot Meets Its First Real Test Tomorrow—Or Does It?

Manulife Financial reports first-quarter 2026 results after the close on May 13, with analysts forecasting $0.79 per share—a 14.49% jump from the same quarter last year. The question is whether Canada's largest insurer can sustain the momentum from its strong Q4 beat and navigate rising expectations as the stock trades near multi-year highs. With shares up sharply over the past month and technical indicators flashing bullish signals, the stakes are high for management to deliver on both earnings and forward guidance.

Part 1: Earnings Preview

Manulife Financial is a Toronto-based multinational insurance and financial services company offering life and health insurance, wealth and asset management, and retirement solutions across Canada, Asia, and the United States (operating as John Hancock). The company serves over 37 million customers globally and is a major player in the North American life insurance sector.

Manulife is scheduled to report Q1 2026 earnings after the market close on Wednesday, May 13, 2026, with a conference call set for 8:00 a.m. ET on May 14. Analysts expect $0.79 per share on revenue of approximately $2.32 billion. The company most recently reported $0.80 per share for Q4 2025, beating estimates by $0.04. Compared to Q1 2025's result of $0.69, the current consensus implies 14.49% year-over-year growth, reflecting optimism about improving underwriting margins and asset management flows.

Three key themes define this earnings story:

Longevity and Wellness Innovation: Manulife launched new longevity and wellness tools in April 2026, drawing positive market reactions. Investors will watch for commentary on customer adoption rates and whether these digital health initiatives are translating into improved persistency and lower claims costs—critical drivers of profitability in the life insurance business.

Capital Management and Dividend Sustainability: The company recently raised its quarterly dividend to $0.485 (annualized $1.94), implying a roughly 4.9% yield. With a payout ratio around 64%, investors are focused on whether strong earnings can support further dividend growth while maintaining capital flexibility for strategic investments and regulatory requirements.

Asia Growth and Market Volatility: As a major player in Asian insurance markets, Manulife's results will be scrutinized for signs of recovery in wealth management flows and the impact of regional economic conditions. Analysts are particularly interested in how the company is navigating interest rate environments across different geographies and whether investment income is meeting expectations.

Ahead of the release, Wall Street maintains a bullish stance. The consensus "Buy" rating with an average price target of $40.75 suggests modest upside from current levels, while recent analyst upgrades—including Canadian Imperial Bank of Commerce's move from "neutral" to "outperform" in January—signal growing confidence in the company's strategic direction and earnings trajectory.

Part 2: Historical Earnings Performance

Manulife has demonstrated a mixed but generally positive earnings track record over the past four quarters. The company beat estimates in two of the last four quarters and missed in two, with surprises ranging from -2.82% to +13.51%.

The most recent quarter (Q4 2025) saw Manulife report $0.80 versus an estimate of $0.76, a +5.26% beat that followed a much stronger +13.51% surprise in Q3 2025 when the company delivered $0.84 against a $0.74 consensus. These back-to-back beats suggest improving operational momentum heading into 2026.

However, the first half of 2025 was more challenging. Q1 and Q2 both produced modest misses of -1.43% and -2.82% respectively, with actual results of $0.69 in each quarter falling slightly short of expectations. The pattern suggests Manulife tends to perform better in the second half of the year, though the company has clearly regained its footing after the early-2025 stumbles. With estimates now calling for $0.79 in Q1 2026—a significant step-up from the $0.69 reported in the year-ago quarter—investors will be watching to see if management can deliver on the higher bar.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Manulife typically reports earnings after market close, meaning Day 0 reflects anticipatory trading before results are released, while Day +1 captures the market's first full reaction to the actual numbers.

Historical price action around Manulife earnings shows meaningful volatility, with an average absolute Day 0 move of 1.69% and Day +1 move of 3.47%. The Day +1 reaction is particularly pronounced, more than doubling the Day 0 anticipation move, which makes sense given the after-close reporting schedule.

The most recent earnings cycle (February 2026) saw a muted Day 0 decline of -0.97% followed by a sharper Day +1 drop of -5.49%, despite the company beating estimates. This suggests investors were disappointed by guidance or underlying trends even as headline EPS came in ahead of expectations. In contrast, the November 2025 report produced a strong +2.65% Day 0 pop and flat Day +1 action, indicating the market had fully priced in the positive surprise by the close of the first session.

Looking further back, the pattern is inconsistent: some quarters see strong Day +1 follow-through (February 2025's +6.85%, May 2024's +5.15%), while others reverse course (August 2025's +1.43% Day 0 followed by -3.81% Day +1). The wide Day +1 range of 4.56% on average underscores the importance of not just beating estimates but delivering commentary that resonates with investors' forward-looking concerns about margins, capital deployment, and growth trajectory.

Part 2.2: Options Market Expected Move

The options market is pricing an expected move of 3.08% for the May 15 expiration, which sits between the historical Day 0 average of 1.69% and the Day +1 average of 3.47%. This suggests options traders are anticipating a typical post-earnings reaction, though slightly below the full Day +1 historical volatility—perhaps reflecting some caution after the sharp sell-off following the last report despite the earnings beat.

Part 3: What Analysts Are Saying

Wall Street maintains a bullish stance on Manulife heading into earnings, with a consensus rating of 4.23 out of 5.0 (solidly in "Buy" territory) based on 13 analysts. The breakdown shows strong conviction: 7 Strong Buys, 2 Moderate Buys, 4 Holds, and zero sell ratings. This lopsided distribution reflects confidence in the company's earnings trajectory and strategic initiatives.

The average price target of $40.75 implies modest upside of approximately 1.8% from the current price of $40.03, with a range from a low of $36.82 to a high of $43.07. While the upside is limited in percentage terms, the tight clustering of estimates and absence of bearish calls suggests analysts see a favorable risk-reward setup with limited downside.

Sentiment has remained unchanged over the past month, with the rating count and average recommendation holding steady at 4.23. This stability indicates analysts are comfortable with their current views and are waiting for the Q1 results to either confirm the bullish thesis or prompt revisions. The lack of recent downgrades is notable given the stock's strong run—shares have climbed significantly above all major moving averages—suggesting the Street believes the rally is justified by fundamentals rather than speculation.

The consensus view appears to be that Manulife is well-positioned to deliver steady earnings growth driven by improving margins, disciplined capital management, and the dividend increase announced earlier this year. However, the modest price target upside also implies that much of the good news may already be reflected in the current valuation, placing added importance on management's forward guidance and commentary about growth drivers in the Asia segment and wealth management business.

Part 4: Technical Picture

Manulife enters earnings with strong technical momentum. The Barchart Technical Opinion currently stands at 88% Buy, unchanged from last week but up sharply from 56% Buy a month ago. This improvement reflects the stock's sustained uptrend and breakout to new highs over the past several weeks.

Timeframe Analysis:

• Short-term (100% Buy): Maximum bullish signal indicates powerful near-term momentum heading into the earnings release
• Medium-term (50% Buy): Moderate buy signal suggests the intermediate trend is constructive but less emphatic than the short-term picture
• Long-term (100% Buy): Maximum bullish reading confirms the broader uptrend remains firmly intact

Trend Characteristics: The trend is characterized as Strong and Strengthening, indicating that momentum is not only positive but accelerating—a supportive backdrop for an earnings catalyst.

Shares are trading at $40.03, positioned above all key moving averages: the 5-day ($39.91), 10-day ($39.40), 20-day ($38.99), 50-day ($36.40), 100-day ($36.64), and 200-day ($34.45). The clean alignment with price above every major average is a textbook bullish setup, though it also means the stock has limited nearby support if earnings disappoint.

The technical picture is unambiguously supportive heading into the release, with the stock riding a strong uptrend and all momentum indicators pointing higher. However, the extended nature of the rally—shares are trading 16.2% above the 200-day moving average—means there's less room for error. A beat-and-raise scenario could propel MFC toward the $43.07 high analyst target, but any disappointment on earnings or guidance could trigger profit-taking back toward the 20-day moving average near $39. The key level to watch is the 50-day moving average at $36.40, which has provided support during the recent rally and would represent a roughly 9% pullback if tested. Overall, the setup favors the bulls, but the stock's strong pre-earnings run means expectations are elevated and the bar for a positive reaction is high.